laurolitsine has been researched along with Diabetes Mellitus, Type 2 in 1 studies
*Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chongming, W; Lin, D; Ning, M; Ruiqi, W; Weiying, L; Xiaopo, Z; Yanan, Y; Yinfeng, T; Yiying, L; Yong, Z; Zhi, Z | 1 |
1 other study(ies) available for laurolitsine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Laurolitsine ameliorates type 2 diabetes by regulating the hepatic LKB1-AMPK pathway and gut microbiota.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Aporphines; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Glucose; Hypoglycemic Agents; Lactic Acid; Liver; Mice; Mice, Inbred C57BL | 2022 |